ARIAD to Host Webcast and Conference Call on Brigatinib Data Presentations at the World Conference on Lung Cancer
02 Dezembro 2016 - 7:05PM
Business Wire
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA), a rare cancer-focused
innovative biotechnology company, today announced a conference call
and webcast to discuss the clinical data presented on brigatinib,
the Company’s investigational anaplastic lymphoma kinase (ALK)
inhibitor, at the International Association for the Study of Lung
Cancer (IASLC) 17th World Conference on Lung Cancer (WCLC). Timothy
P. Clackson, Ph.D., president of research and development and chief
scientific officer of ARIAD will host the call. Dr. Clackson will
be joined by Karen Reckamp, MD, associate professor in the
Department of Medical Oncology & Therapeutics Research and
co-director of the Lung Cancer and Thoracic Oncology Program at
City of Hope Comprehensive Cancer Center (COHCCC). The call will be
held Wednesday, December 7, 4:00 p.m. Central European Time (10:00
a.m. Eastern Time).
The live webcast can be accessed by visiting the investor
relations section of the Company’s website
at http://investor.ariad.com. The call can be accessed by
dialing 844-249-9386 (domestic) or 270-823-1534 (international)
five minutes prior to the start time and providing the pass code
20888507. A replay of the call will be available on the ARIAD
website approximately two hours after completion of the call and
will be archived for three weeks.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts is focused on discovering, developing and
commercializing precision therapies for patients with rare cancers.
ARIAD is working on new medicines to advance the treatment of rare
forms of chronic and acute leukemia, lung cancer and other rare
cancers. ARIAD utilizes computational and structural approaches to
design small-molecule drugs that overcome resistance to existing
cancer medicines. For additional information, visit
http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161202005681/en/
ARIAD Pharmaceuticals, Inc.For InvestorsManmeet
Soni, (617) 503-7298manmeet.soni@ariad.comorFor MediaLiza
Heapes, (617) 621-2315liza.heapes@ariad.com
Ariad (NASDAQ:ARIA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Ariad (NASDAQ:ARIA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
Notícias em tempo-real sobre Ariad Pharmaceuticals, Inc. da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Ariad Pharmaceuticals, Inc. (MM)